TSXV •
Healthcare •
Biotechnology •
Quote as of 08/11/2026 14:46
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTSXV
Market Capitalization55.03 mln
Float53.32 mln
Earnings Date08/28/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
91
/ 100
Top performer
Debt / Equity
-0.70
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0%
No payout
Business Description
Arch Biopartners is a Toronto-based Canadian drug development company focused on protecting kidneys and organs from serious injury. Its most advanced treatment, LSALT Peptide, is currently in Phase 2 clinical trials for patients who develop kidney inflammation following open-heart surgery, while a second compound called cilastatin targets a different form of kidney damage caused by harmful toxins. The company is also building a pipeline of treatments aimed at chronic kidney disease.
